Abstract: The invention provides peptides which are potent in stimulating the release of pituitary GH in fish and amphibians which have a substantial portion or all of the following sequence: R.sub.1 -R.sub.2 -R.sub.3 -R.sub.4 -R.sub.5 -Phe-R.sub.7 -R.sub.8 -R.sub.9 -Tyr-Arg-R.sub.12 -R.sub.13 -Leu-R.sub.15 -Gln-Leu-R.sub.18 -Ala-Arg-Lys-R.sub.22 -Leu-R.sub.24 -R.sub.25 -R.sub.26 -R.sub.27 -R.sub.28 -R.sub.29 -R.sub.30 -R.sub.31 -Gly-R.sub.33 -R.sub.34 -R.sub.35 -R.sub.36 -R.sub.37 -R.sub.38 -R.sub.39 -R.sub.40 -R.sub.41 -R.sub.42 -R.sub.43 -R.sub.44 -Ser wherein R.sub.1 is N-Me Tyr, Tyr, desNH.sub.2 -Tyr, D-Tyr, N-Et Tyr, N-Ip Tyr, N-Me His, His, desNH.sub.2 -His, D-His, N-Et His, and N-Ip His; R.sub.2 is Ala, D-Ala or D-NMA; R.sub.3 is Asp or D-Asp; R.sub.4 is Gly or Ala; R.sub.5 and R.sub.27 are selected from the group consisting of Met, Leu, Val, Nva, Gln, Thr, Ile, Ala, Arg, Asn, Asp, Cys, Glu, Gly, His, Nle, Lys, Phe, Pro, Ser, Tyr and Trp; R.sub.7 is Asn or Thr; R.sub.8 is Lys, Asn or Ser; R.sub.

Abstract: Synthetic peptides which possess the ability to specifically induce the differentiation of precursor B cells into mature B-cells capable of producing antibody.

Abstract: A bioelastomer containing elastomeric units comprising tetrapeptide, or pentapeptide or units thereof modified by hexapeptide repeating units and mixtures thereof, wherein said repeating units comprise amino acid residues selected from the group consisting of hydrophobic amino acid and glycine residues, wherein said repeating units exist in a conformation having a .beta.-turn which comprises a polypentapeptide unit of the formula:--X.sup.1 --(IPGVG).sub.n --Y.sup.1 --whereinI is a peptide-forming residue of L-isoleucine;P is a peptide-forming residue of L-proline;G is a peptide-forming residue of glycine;V is a peptide-forming residue of L-valine; andwherein X.sup.1 is PGVG, GVG, VG, G or a covalent bond; Y.sup.1 is IPGV, IPG, IP, I or a covalent bond; and n is an integer from 1 to 200, or n is 0, with the proviso that X.sup.1 and Y.sup.

Abstract: The invention provides physically stable anthelmintic paste compositions containing resinates of d1-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole and other anthelmintic compounds in combination with a wide variety of therapeutic agents such as antibiotics, vitamins, vaccines, or mineral supplements.

Abstract: A dispenser is disclosed for delivering a beneficial agent formulation to a warm, fluid environment of use. The dispenser comprises an outer semipermeable wall surrounding and laminating an inner hydrophilic, swellable wall. The walls define an interior space for containing a thermo-responsive beneficial agent formulation. A passageway through the semipermeable wall connects the exterior of the dispenser through an opening in the inside wall with the interior of the dispenser.

Abstract: The present invention concerns a new antibiotic substance denominated antibiotic A 40926 mannosyl aglycon and the addition salts thereof, a process for preparing it from antibiotic A 40926 complex or a factor thereof, and its use in the treatment of infectious disease involving microorganisms susceptible to it.

Abstract: Renin inhibitory peptides of the formula ##STR1## and analogs thereof inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosteronism.

Abstract: A hormone composition for producing superovulation in cattle. The composition has a particular ratio of follicle stimulating hormone (FSH) and luteinizing hormone (LH) which produces an optimum superovulation response in cattle. The composition can be produced from animal pituitary glands or by recombinant DNA procedures.

Abstract: A composition for eliciting production of antibody to hepatitis B surface antigen and method of neutralizing the infectivity of hepatitis type B virus. A cyclic polypeptide is prepared having a disulfide bond in a hydrophilic region, namely residues 117-137 or 122-137 and an amino acid sequence unique from that associated with the native 25,000 molecular weight polypeptide derived from hepatitis B surface antigen.

Abstract: A series of seventeen synthetic peptides which are capable of raising antibodies specific for certain desired human papilloma virus (HPV) are useful in diagnosis and therapy of conditions associated with HPV infection.

Abstract: A method of treatment of breast cancer in susceptible animals whose ovarian hormonal secretions were previously blocked by surgical or chemical means, e.g., by use of an LH-RH agonist, e.g., [D-Trp.sup.6, des-Gly-NH.sub.2.sup.10 ]LH-RH ethylamide with a combination therapy comprising administering an antiandrogen, e.g., flutamide and an antiestrogen, e.g., Tamoxifen, pharmaceutical compositions useful for such treatment and two and three component pharmaceutical kits containing such compositions are disclosed.

Abstract: A two-step process of immobilization of biologically efficient compounds is disclosed, in which the biologically efficient compounds are bonded from an aqueous solution by a hydrolytically stable linkage to a macroporous polymeric carrier containing reactive functional groups. In the first step, a hydrophobic adsorption occurs of the biologically efficient compounds on a macroporous matrix of the carrier, and an increase of their concentration on the solid surface. In the second step, the reaction takes place with the reactive functional groups of the carrier, and a covalent linkage is formed. The hydrophobic adsorption of compounds determined for immobilization is achieved by the addition of inorganic salts in a concentration from 0.5 to 3.0 mol/l. The invention can be utilized in the preparation of enzymatic catalysts for transformations of compounds and in the preparation of specific sorbents for both analytical and preparative affinity chromatography.

Abstract: A method of treatment of breast cancer in susceptible animals whose ovarian hormonal secretions are blocked by surgical or chemical means, e.g., by use of an LH-RH agonist, e.g., [D-Trp.sup.6, des-Gly-NH.sub.2.sup.10 ]LH-RH ethylamide with a therapy comprising administering an antiandrogen, e.g., flutamide and an optionally, an inhibitor of adrenal sex steroid biosynthesis e.g., aminoglutethimide, pharmaceutical compositions useful for such treatment and two, four and five component pharmaceutical kits containing such compositions are disclosed.

Abstract: There is provided a composite sheet material for fabrication of storage envelopes for magnetic recording media, e.g., floppy diskettes. The material has a low debris count, and a fast rate of static decay as well as high stiffness and strength.

Abstract: Novel cytotoxic agents are provided as small polypeptides related to a low molecular weight peptide derived from Crotalus atrox. The compounds may be used by themselves or in combination with other reagents, such as antibodies, for inhibiting cell growth.

Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.

Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.

Abstract: A process for the manufacture of a polypeptide (I) having the formula: ##STR1## which comprises steps of: (a) coupling, successively and in the order of the sequence of the polypeptide (I), the four protected fragments A, B, C and D or five protected fragments A, B, C, E and F,said fragment A by the formula, Leu-Gin-Asp-Ile-Met-Ser-Arg-NH.sub.2said fragment B by the formula, Gln-Leu-Ser-Ala-Arg-Lys-Leusaid fragment C by the formula, Arg-Lys-Val-Leu-Glysaid fragment D by the formula, Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyrsaid fragment E by the formula, Ile-Phe-Thr-Asn-Ser-Tyrand said fragment F by the formula, Tyr-Ala-Asp-Ala being represented, respectively, and(b) eliminating, at the end of sequence, all the protecting groups to provide the polypeptide (I) which is active on the stimulation of the release of the growth hormone and thus is very useful as medicine for treatment of growth hormone deficiency disease and the like.

Abstract: Process for manufacturing oxymethylene copolymers stabilized against thermal degradation, comprising the heating of the copolymer in a medium containing water and a disubstituted cellulose ether.

Abstract: Peptides wherein an amide bond is replaced by nonhydrolyzable isosteric linkage are disclosed as thrombogenic inhibitors.